Bellone M - Search Results

1

Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.

Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, Calcinotto A, Freschi M, Mondino A, Galli R, Bellone M. Jachetti E, et al. Among authors: bellone m. Oncoimmunology. 2013 May 1;2(5):e24520. doi: 10.4161/onci.24520. Epub 2013 Apr 16. Oncoimmunology. 2013. PMID: 23762811 Free PMC article.

2

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.

Bellone M, Iezzi G, Martin-Fontecha A, Rivolta L, Manfredi AA, Protti MP, Freschi M, Dellabona P, Casorati G, Rugarli C. Bellone M, et al. J Immunol. 1997 Jan 15;158(2):783-9. J Immunol. 1997. PMID: 8992995

3

Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.

Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Mondino A, Bellone M. Camporeale A, et al. Among authors: bellone m. Cancer Res. 2003 Jul 1;63(13):3688-94. Cancer Res. 2003. PMID: 12839960

4

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.

Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M. Degl'Innocenti E, et al. Among authors: bellone m. Eur J Immunol. 2005 Jan;35(1):66-75. doi: 10.1002/eji.200425531. Eur J Immunol. 2005. PMID: 15597325 Free article.

5

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration.

Casati A, Zimmermann VS, Benigni F, Bertilaccio MT, Bellone M, Mondino A. Casati A, et al. Among authors: bellone m. J Immunol. 2005 Mar 15;174(6):3317-25. doi: 10.4049/jimmunol.174.6.3317. J Immunol. 2005. PMID: 15749863

6

Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses.

Iezzi G, Boni A, Degl'Innocenti E, Grioni M, Bertilaccio MT, Bellone M. Iezzi G, et al. Among authors: bellone m. J Immunol. 2006 Aug 15;177(4):2131-7. doi: 10.4049/jimmunol.177.4.2131. J Immunol. 2006. PMID: 16887972

7

Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T lymphocytes.

Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Jachetti E, Camporeale A, Bellone M. Boni A, et al. Among authors: bellone m. Eur J Immunol. 2006 Dec;36(12):3157-66. doi: 10.1002/eji.200535597. Eur J Immunol. 2006. PMID: 17111344 Free article.

8

Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.

Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MT, Hess-Michelini R, Doglioni C, Bellone M. Degl'Innocenti E, et al. Among authors: bellone m. Cancer Res. 2008 Jan 1;68(1):292-300. doi: 10.1158/0008-5472.CAN-07-2429. Cancer Res. 2008. PMID: 18172322

9

Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.

Bellone M, Mondino A, Corti A. Bellone M, et al. Trends Immunol. 2008 May;29(5):235-41. doi: 10.1016/j.it.2008.02.003. Epub 2008 Mar 28. Trends Immunol. 2008. PMID: 18375183 Review.

10

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, Greenberg NM, Corti A, Bellone M. Bertilaccio MT, et al. Among authors: bellone m. Prostate. 2008 Jul 1;68(10):1105-15. doi: 10.1002/pros.20775. Prostate. 2008. PMID: 18437689

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters